

Nancy U Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8264851/publications.pdf>

Version: 2024-02-01

186
papers

22,067
citations

13099

68
h-index

9861

141
g-index

219
all docs

219
docs citations

219
times ranked

24011
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	7.7	46
2	Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 201-210.	2.5	0
3	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1258-1267.	7.0	31
4	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	1.6	23
5	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238.	1.2	11
6	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162.	1.6	18
7	p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 1473.	12.8	10
8	Identification and Management of Pathogenic Variants in <i>BRCA1</i> , <i>BRCA2</i> , and <i>PALB2</i> in a Tumor-Only Genomic Testing Program. <i>Clinical Cancer Research</i> , 2022, 28, 2349-2360.	7.0	8
9	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
10	Adapting and Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care (Project ADAPT): Protocol for an Implementation Science-Based Study. <i>JMIR Research Protocols</i> , 2022, 11, e35736.	1.0	0
11	Management of Advanced Human Epidermal Growth Factor Receptor -Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2636-2655.	1.6	34
12	STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	68
13	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor -Positive Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 2612-2635.	1.6	60
14	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor -Positive, Human Epidermal Growth Factor Receptor -Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	1.6	42
15	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 82-92.	3.8	6
16	The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2511-2521.	3.6	7
17	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	3.0	11
18	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 1105-1118.	7.0	24
20	Clinical behavior of recurrent hormone receptorâ€“positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1â€“98 clinical trial. Cancer, 2021, 127, 700-708.	4.1	2
21	Using Quality Improvement to Increase Access to Palliative Care. JCO Oncology Practice, 2021, 17, 107-110.	2.9	2
22	Management and outcomes of men diagnosed with primary breast cancer. Breast Cancer Research and Treatment, 2021, 188, 561-569.	2.5	7
23	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. JAMA Oncology, 2021, 7, 609.	7.1	15
24	Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 3059-3059.	1.6	0
25	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. Journal of Clinical Oncology, 2021, 39, 10528-10528.	1.6	1
26	Survival in male breast cancer (MaBC) over the past three decades.. Journal of Clinical Oncology, 2021, 39, 569-569.	1.6	0
27	Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer, 2021, 21, 568.	2.6	10
28	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	3.7	16
29	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 189, 411-423.	2.5	3
30	Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 797-804.	4.9	11
31	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology, 2021, 39, 2667-2675.	1.6	58
32	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	12.8	19
33	Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist, 2021, 26, 927-933.	3.7	5
34	Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal of the National Cancer Institute, 2021, 113, 355-359.	6.3	10
35	Reply to J. Wei et al. Journal of Clinical Oncology, 2021, , JCO2101973.	1.6	1
36	Perceptions of patients with early stage breast cancer toward research biopsies. Cancer, 2021, 127, 1208-1219.	4.1	3

#	ARTICLE	IF	CITATIONS
37	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2021, 5, 1777-1787.	3.0	5
38	Integrative multiomics-histopathology analysis for breast cancer classification. Npj Breast Cancer, 2021, 7, 147.	5.2	21
39	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	27.0	363
40	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research and Treatment, 2020, 179, 113-123.	2.5	26
41	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2.	2.4	21
42	Patterns of recurrence and metastasis in <i>BRCA1/BRCA2</i>-associated breast cancers. Cancer, 2020, 126, 271-280.	4.1	74
43	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, e20-e26.	2.4	5
44	Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. Oncologist, 2020, 25, 310-318.	3.7	92
45	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 597-609.	27.0	789
46	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.7	0
47	53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). Neuro-Oncology Advances, 2020, 2, ii11-ii11.	0.7	1
48	Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. JCO Precision Oncology, 2020, 4, 1084-1097.	3.0	11
49	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.0	60
50	Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Research, 2020, 22, 131.	5.0	31
51	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 5310-5319.	7.0	102
52	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 5974-5989.	7.0	87
53	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	1.6	276
54	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer. JAMA Oncology, 2020, 6, 1598.	7.1	84

#	ARTICLE	IF	CITATIONS
55	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	10.1	104
56	Response to Letter to Editor. <i>Neuro-Oncology</i> , 2020, 22, 1706-1707.	1.2	1
57	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. <i>Journal of Clinical Oncology</i> , 2020, 38, 3773-3784.	1.6	223
58	Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases. <i>Annals of Oncology</i> , 2020, 31, 1279-1281.	1.2	3
59	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1174-1193.	9.4	176
60	Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. <i>Annals of Oncology</i> , 2020, 31, 1231-1239.	1.2	30
61	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
62	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
63	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. <i>Clinical Breast Cancer</i> , 2020, 20, 395-401.e3.	2.4	7
64	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	7.0	109
65	Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib. <i>JCO Precision Oncology</i> , 2020, 4, 572-578.	3.0	31
66	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. <i>Neuro-Oncology</i> , 2020, 22, 1359-1367.	1.2	49
67	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	1.2	131
68	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 334-343.	0.8	81
69	Subtype switching in breast cancer brain metastases: a multicenter analysis. <i>Neuro-Oncology</i> , 2020, 22, 1173-1181.	1.2	65
70	Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 147-155.	2.5	5
71	Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	7.0	138
72	Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2390-2397.	1.6	9

#	ARTICLE	IF	CITATIONS
73	HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> -Amplified or Mutant Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 674-687.	9.4	149
74	Clinical Trials: Endpoints and Outcome Assessment. , 2020, , 407-421.		0
75	Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. <i>Oncologist</i> , 2019, 24, 595-602.	3.7	8
76	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78.	5.0	141
77	Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. <i>Oncologist</i> , 2019, 24, e441-e449.	3.7	36
78	MLTI-16. SYSTEMIC THERAPY FOLLOWING CRANIOTOMY IN PATIENTS WITH A SOLITARY BREAST CANCER BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i17-i17.	0.7	0
79	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	9.4	778
80	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. <i>Clinical Cancer Research</i> , 2019, 25, 6392-6405.	7.0	37
81	Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases. <i>World Neurosurgery</i> , 2019, 128, e157-e164.	1.3	5
82	Systemic Therapy of Central Nervous System Metastases of Breast Cancer. <i>Current Oncology Reports</i> , 2019, 21, 49.	4.0	26
83	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	2.5	15
84	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	1.6	251
85	Central Nervous System Metastases in HER2-Positive Breast Cancer. , 2019, , 75-93.		0
86	Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis. <i>Npj Breast Cancer</i> , 2019, 5, 46.	5.2	26
87	Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. <i>Nature Biomedical Engineering</i> , 2019, 3, 230-245.	22.5	127
88	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. <i>Nature Genetics</i> , 2019, 51, 207-216.	21.4	170
89	Breast cancer-specific survival by age: Worse outcomes for the oldest patients. <i>Cancer</i> , 2018, 124, 2184-2191.	4.1	46
90	Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. <i>Clinical Cancer Research</i> , 2018, 24, 1795-1804.	7.0	67

#	ARTICLE	IF	CITATIONS
91	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	10.7	87
92	Attitudes of patients with metastatic cancer towards research biopsies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 231-238.	1.1	1
93	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	1.6	93
94	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 505-507.	2.5	9
95	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	1.6	162
96	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	1.6	141
97	Implications of Screening for Brain Metastases in Patients With Breast Cancer and Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 1001.	7.1	44
98	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 10.	5.2	95
99	Update on managing brain metastases in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 598-601.	0.3	3
100	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	10.7	1,612
101	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
102	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	1.2	137
103	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
104	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 316-324.	4.9	3
105	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	12.8	584
106	Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. <i>Clinical Chemistry</i> , 2017, 63, 1605-1613.	3.2	23
107	Imaging in the evaluation and follow-up of early and advanced breast cancer: When, why, and how often?. <i>Breast</i> , 2017, 31, 318-324.	2.2	27
108	Implementation of Surgeon-Initiated Gene Expression Profile Testing (Onco<i>type</i> DX) Among Patients With Early-Stage Breast Cancer to Reduce Delays in Chemotherapy Initiation. <i>Journal of Oncology Practice</i> , 2017, 13, e815-e820.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncologyâ€”Friends of Cancer Research Brain Metastases Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3760-3773.	1.6	91
110	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 3737-3744.	1.6	331
111	Prior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process. <i>Journal of Oncology Practice</i> , 2017, 13, e273-e282.	2.5	30
112	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 45-56.	3.8	24
113	Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 45-56.	3.8	14
114	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016, 122, 1169-1177.	4.1	87
115	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	1.2	209
116	RECIST 1.1â€”Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016, 62, 132-137.	2.8	1,143
117	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study. <i>Breast</i> , 2016, 29, 68-73.	2.2	8
118	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. <i>Breast</i> , 2016, 30, 136-140.	2.2	4
119	Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1519-1526.	4.9	17
120	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	30.7	105
121	RECIST 1.1 â€” Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	2.8	211
122	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2â€”Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016, 34, 945-952.	1.6	148
123	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1460-1468.	1.6	413
124	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2015, 20, 992-1000.	3.7	8
125	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	10.7	711
126	Better treatments needed for breast cancer brain metastases. <i>Lancet Oncology</i> , The, 2015, 16, 1583-1584.	10.7	10

#	ARTICLE	IF	CITATIONS
127	Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. <i>Cancer</i> , 2015, 121, 1937-1948.	4.1	8
128	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	1.6	49
129	Reply to H.L. McArthur et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 125-125.	1.6	4
130	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
131	Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center. <i>Annals of Surgical Oncology</i> , 2015, 22, 428-434.	1.5	6
132	Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 697-707.	2.5	32
133	Weighing the Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1530-1533.	1.6	2
134	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18297-18302.	7.1	104
135	Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. <i>Stat</i> , 2014, 3, 172-186.	0.4	3
136	Targeted Therapies in Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2014, 16, 276.	1.8	42
137	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.5	59
138	Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150.	1.6	207
139	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
140	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	1.6	303
141	Use and Duration of Chemotherapy in Patients With Metastatic Breast Cancer According to Tumor Subtype and Line of Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 71-80.	4.9	36
142	Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 347-354.	0.1	20
143	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 307.	1.1	48
144	CNS Metastases in Breast Cancer: Old Challenge, New Frontiers. <i>Clinical Cancer Research</i> , 2013, 19, 6404-6418.	7.0	162

#	ARTICLE	IF	CITATIONS
145	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	10.7	116
146	A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 403-410.	2.5	17
147	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 405-414.	2.5	60
148	Prospective clinical experience with research biopsies in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 203-209.	2.5	13
149	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	10.7	119
150	Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. <i>Annals of Oncology</i> , 2013, 24, 283-291.	1.2	57
151	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€”MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	2.2	77
152	Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. <i>Breast</i> , 2013, 22, 525-531.	2.2	102
153	Brain metastases in HER2-positive breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 185-186.	10.7	10
154	Attitudes of patients with metastatic breast cancer toward research biopsies. <i>Annals of Oncology</i> , 2013, 24, 1853-1859.	1.2	26
155	Follow-Up after Breast Cancer Diagnosis. <i>Breast Care</i> , 2013, 8, 457-460.	1.4	2
156	Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 513-513.	1.6	29
157	Brain metastasis. <i>Current Opinion in Neurology</i> , 2012, 25, 786-794.	3.6	20
158	Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. <i>Breast Cancer Research</i> , 2012, 14, R129.	5.0	114
159	Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 153-160.	2.5	107
160	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 2111-2117.	0.8	321
161	Importance of Extracranial Disease Status and Tumor Subtype for Patients Undergoing Radiosurgery for Breast Cancer Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e479-e486.	0.8	24
162	Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 419-425.	1.6	1,205

#	ARTICLE	IF	CITATIONS
163	Salvage stereotactic radiosurgery for breast cancer brain metastases. <i>Cancer</i> , 2012, 118, 2014-2020.	4.1	29
164	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. <i>Cancer</i> , 2012, 118, 5463-5472.	4.1	469
165	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1057-1065.	2.5	183
166	HSP90 as a platform for the assembly of more effective cancer chemotherapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 756-766.	4.1	74
167	A randomized phase III double-blinded placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-overexpressing metastatic breast cancer (HER2+ MBC): A trial of the Eastern Cooperative Oncology Group (E1105).. <i>Journal of Clinical Oncology</i> , 2012, 30, 605-605.	1.6	12
168	The ethical use of mandatory research biopsies. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 620-625.	27.6	60
169	EMBRACE, eribulin, and new realities of advanced breast cancer. <i>Lancet, The</i> , 2011, 377, 878-880.	13.7	10
170	A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases. <i>Clinical Breast Cancer</i> , 2011, 11, 376-383.	2.4	42
171	Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2011, 105, 613-620.	2.9	149
172	Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 129-131.	2.5	7
173	Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology. <i>Journal of Clinical Oncology</i> , 2010, 28, 2635-2640.	1.6	76
174	Geographic Distribution of Lapatinib-Induced Skin Rash: Sparing of Abdominal Skin Persists in the Transverse Rectus Abdominis Myocutaneous Flap. <i>Journal of Clinical Oncology</i> , 2009, 27, e218-e219.	1.6	3
175	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1452-1459.	7.0	592
176	Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. <i>Cancer</i> , 2008, 113, 2638-2645.	4.1	585
177	Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2008, 26, 798-805.	1.6	112
178	Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1993-1999.	1.6	430
179	Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Metastases: A Feasibility Study. <i>Radiology</i> , 2007, 245, 824-830.	7.3	37
180	Brain Metastases: The HER2 Paradigm. <i>Clinical Cancer Research</i> , 2007, 13, 1648-1655.	7.0	361

#	ARTICLE	IF	CITATIONS
181	Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Investigational New Drugs, 2007, 25, 369-375.	2.6	35
182	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Research, 2006, 8, R66.	5.0	123
183	New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Research, 2004, 6, 204-10.	5.0	55
184	CNS Metastases in Breast Cancer. Journal of Clinical Oncology, 2004, 22, 3608-3617.	1.6	644
185	BMS-247550 Bristol-Myers Squibb/GBF. Current Opinion in Investigational Drugs, 2003, 4, 746-56.	2.3	5
186	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncology, 0, , .	7.1	51